What do systematic reviews say?

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 8485 participants
  Moderate

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  HR 0.94 [0.74, 1.2]
  2 studies · 1243 participants
  Low

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 1.11 [0.78, 1.59]
  1 study · 284 participants
  Moderate

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in recurrent VTE compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.46 [0.16, 1.32]
  1 study · 270 participants
  Low

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 1.11 [0.35, 3.56]
  1 study · 270 participants
  Low

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

The review found no eligible studies for this question.

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.59 [0.44, 0.8]
  4 studies · 1712 participants
  Moderate

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

The review found no eligible studies for this question.

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  HR 0.49 [0.31, 0.78]
  2 studies · 1243 participants
  Moderate

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 1.09 [0.55, 2.12]
  4 studies · 1712 participants
  Low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.78 [0.47, 1.27]
  4 studies · 1712 participants
  Very low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.94 [0.52, 1.69]
  1 study · 138 participants
  Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.94 [0.72, 1.23]
  4 studies · 1060 participants
  Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.63 [0.34, 1.15]
  4 studies · 1050 participants
  Low

Acupuncture vs vitamin B12

It is very uncertain whether acupuncture changes overall clinical improvement at short‐term compared with vitamin B12 (very low certainty).

• Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome 2018 · Cochrane Headline outcomes only
  RR 1.16 [0.99, 1.36]
  2 studies · 100 participants
  Very low

Acupuncture vs vitamin B12

The review found no eligible studies for this question.

• Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupuncture vs vitamin B12

• Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Steroids vs vitamin D

Steroid probably leads to higher number of participants achieving 'clearance' by IGA compared with vitamin D (moderate certainty).

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  RR 1.82 [1.52, 2.18]
  4 studies · 2180 participants
  Moderate

Steroids vs vitamin D

Steroid leads to higher number of participants achieving 'response' by IGA compared with vitamin D (high certainty).

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  RR 2.09 [1.8, 2.41]
  3 studies · 1827 participants
  High

Steroids vs vitamin D

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported